Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information (Tables)

v3.25.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2024
Segment Information [Abstract]  
Schedule of Consolidated Statements of Operations

Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company’s consolidated statements of operations, regularly reviewed by our CODM, include salaries and clinical trials expenses and presented below.

 

    Year ended
December 31,
 
    2024     2023  
             
Operating expenses:            
Salaries and related expenses, other than share-based compensation     10,507       8,350  
Clinical trials     12,301       8,270  
Stock based compensation     1,848       1,059  
Depreciation expenses     1,803       871  
Goodwill, IPR&D and long-lived assets impairment     8,084      
-
 
Other segment items (*)     9,980       6,798  
Total Operating expenses     44,523       25,348  

 

(*) Other segment items include all remaining costs necessary to operate our business, which primarily include external professional services, rent, insurance and other administrative expenses, net of grants received.
Schedule of Consolidated Balance Sheets

The Company's Property and equipment, as well as the Company's operating lease right-of-use assets recognized on the consolidated balance sheets were located as follows:

 

    As of December 31,  
    2024     2023  
Israel     6,090       7,397  
United States     4,412      
-
 
Total     10,502       7,397